Uniwersytecki Szpital Kliniczny Nr 1 Im Norberta Barlickiego Uniwersytetu Medycznego W Lodzi SPZOZ

The Szpital Kliniczny nr 1 Oddział Kliniczny Pulmonologii i Alergologii in Lodz is especially active in respiratory research, with studies focused on conditions such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and pulmonary sarcoidosis. These trials are mainly designed to test new treatments, assess symptom control, and improve lung function and overall disease management.

• Testing new therapies for idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease
• Evaluating treatment options for asthma and COPD with frequent exacerbations
• Studying approaches to reduce cough, inflammation, and corticosteroid use in chronic lung disease

Several projects also explore longer-term safety and real-world benefit, helping define how emerging respiratory treatments may support patients with persistent and progressive lung disorders.

This site also contributes to immune system disease research, including trials in allergic rhinitis, rhinoconjunctivitis, and pulmonary sarcoidosis. The main goal is to evaluate whether new therapies can better control inflammation, reduce symptoms, and improve quality of life for people with chronic allergic and immune-mediated conditions.

• Assessing subcutaneous immunotherapy for house dust mite allergy-related symptoms
• Exploring novel treatment strategies for pulmonary sarcoidosis
• Measuring how well investigational approaches reduce the need for background steroid treatment

These studies reflect a strong focus on both symptom relief and disease control in conditions driven by immune and allergic pathways.

The clinical trial portfolio includes research in cardiovascular disease, particularly studies involving acute ischemic stroke and high-risk transient ischemic attack. The purpose is to determine whether new antithrombotic treatment strategies can help lower the risk of recurrent events after a serious cerebrovascular episode.

• Reducing the chance of another stroke or related vascular event
• Evaluating a new approach to secondary prevention after transient ischemic attack
• Improving protection for patients at high risk of further ischemic complications

This area broadens the site’s research beyond pulmonary care, linking specialist hospital expertise with prevention-focused cardiovascular studies.

Research at this clinical site also includes digestive system disease studies in ulcerative colitis. These trials are intended to compare investigational treatment with established therapy and to better understand how well it can control intestinal inflammation and improve clinical response.

• Evaluating treatment effectiveness in ulcerative colitis
• Comparing a new therapy with a licensed option for inflammatory bowel disease
• Assessing safety alongside symptom improvement in chronic gastrointestinal inflammation

Although smaller in volume than the respiratory program, this work adds an important gastrointestinal dimension to the site’s broader clinical research profile.

The site is involved in studies related to hormonal disease, especially secondary hyperparathyroidism in people with end-stage kidney disease receiving hemodialysis. The aim is to test whether new treatment options can better control hormone-related complications and support long-term patient management.

• Testing therapies for secondary hyperparathyroidism
• Monitoring changes in hormone levels in patients on maintenance hemodialysis
• Improving control of complications linked to advanced kidney disease

This research reflects an interest in complex metabolic and endocrine problems that often accompany chronic illness.

The trial portfolio also touches on male urogenital disease through research in patients with chronic kidney-related conditions, where treatment goals include better management of long-term complications and improved overall care. While not the dominant focus, this area contributes to the hospital’s multidisciplinary research activity.

• Supporting studies in patients with advanced kidney disease
• Addressing complications that affect urinary and reproductive health
• Exploring therapies aimed at improving chronic disease control

These projects add breadth to the site’s clinical research, complementing its stronger expertise in respiratory and immune disorders.

The site’s broader research profile includes female urogenital disease and pregnancy-related complications, though these topics appear less prominently than respiratory studies. The trials in this area are part of a wider effort to evaluate new treatments for complex chronic conditions that can affect women’s health.

• Investigating treatment approaches relevant to women’s health
• Supporting management of complications linked to chronic disease
• Expanding the hospital’s clinical research reach across multiple specialties

Together, these studies show a diverse research environment at Uniwersytecki Szpital Kliniczny Nr 1 Im Norberta Barlickiego Uniwersytetu Medycznego W Lodzi SPZOZ, with a clear emphasis on chronic disease care and treatment innovation.